Organogenesis Holdings (ORGO) said late Monday the independent data monitoring committee for its second phase 3 trial of ReNu to manage symptoms related to knee osteoarthritis recommended that the study proceed without modification and without increase to the sample size.

The committee also found the safety data to be consistent with the known safety profile for ReNu, the company said.

The 594-patient trial involves the ReNu amniotic suspension allograft to treat moderate to severe symptomatic knee osteoarthritis, a degenerative joint disease

The company's shares were up more than 5% in after-hours activity.